GLP-1 and Anhedonia: What the Evidence Says

Possibly, in some people, but the evidence is limited. Anhedonia is not a listed or established side effect of approved GLP-1 compounds, and large clinical trials haven’t identified it as a common problem. However, a small number of case reports and many anecdotal reports suggest it may occur in some users.

Doctors have noted that people have anecdotally described anhedonia-like symptoms on GLP-1s, but very little has been formally published on it.

The theory behind GLP-1 anhedonia comes from how these compounds work in the brain. GLP-1 receptors are found in reward-related brain regions, including areas tied to dopamine signaling. Researchers have noted this may suggest a possible link to symptoms like anhedonia.

This is the same system that helps GLP-1s reduce “food noise,” cravings, and even alcohol intake in some people. Some researchers think that in certain people, the effect may extend beyond food to other sources of pleasure. This remains a hypothesis, not a proven effect.

Semaglutide (Ozempic, Wegovy)

Semaglutide has the most real-world use and the most adverse event reports. An analysis of FDA and WHO adverse event databases highlighted semaglutide’s potential psychiatric risks, particularly in female patients. These databases show reported events, not proof that the compound caused them.

Tirzepatide (Mounjaro, Zepbound)

A 2025 case report described three patients who developed anhedonia after starting tirzepatide. Two improved after lowering their dose, and one needed an added treatment. The authors said the finding needs confirmation in more rigorous studies.

Retatrutide

Retatrutide is an investigational triple agonist (GLP-1, GIP, and glucagon) and is not FDA-approved. Anhedonia hasn’t been reported as a notable side effect in its published trial results. Online claims that “reta” causes anhedonia or makes people “fall out of love” have spread widely, but a physician interviewed by CTV News called these claims theoretical, since no evidence supports them so far.

Overall, they appear uncommon. In one analysis of European adverse event reports, psychiatric events made up only about 1.2% of total reports for semaglutide, liraglutide, and tirzepatide. Researchers still recommend monitoring, especially for depression, anxiety, and suicidal thoughts.

• Clinical trials often exclude people with psychiatric conditions, the group most vulnerable to mood side effects.
• Trials may be too short to catch delayed effects.
• Adverse event reports can’t prove cause and effect.
• Unregulated products, including compounded and research-chemical GLP-1s, make anecdotal reports harder to interpret.

• Losing interest in hobbies or activities you enjoy
• Feeling emotionally flat or numb
• Reduced motivation
• Less enjoyment from social time or relationships
• Lower libido

These symptoms can have many causes, including rapid weight loss, low calorie intake, poor sleep, or underlying depression.

• Talk to your healthcare provider. In tirzepatide case reports, lowering the dose helped some patients.
• Don’t stop or change a prescribed medication on your own without medical guidance.
• Check your nutrition and sleep. Very low calorie intake can affect mood and energy.
• Avoid unregulated products. Compounded or research-chemical GLP-1s may not contain what the label claims.

If low mood becomes severe, or you have thoughts of self-harm, contact a healthcare professional right away or call or text 988 (the Suicide & Crisis Lifeline in the US).

• Can Ozempic cause anhedonia? Some people report it, and semaglutide has shown a psychiatric signal in adverse event databases, but anhedonia isn’t an established side effect.
• Can Zepbound or Mounjaro cause anhedonia? A small case report described anhedonia in three tirzepatide patients, and some improved after a dose reduction.
• Does retatrutide cause anhedonia? There’s no clinical evidence that it does. Reports are anecdotal.
• Do GLP-1s affect dopamine? GLP-1 receptors are found in reward-related brain areas linked to dopamine, which may explain reduced cravings. Effects on mood are still being studied.
• Is GLP-1 anhedonia permanent? There’s no data showing it’s permanent. In case reports, symptoms improved after dose changes.

• Anhedonia is a reduced ability to feel pleasure.
• GLP-1 anhedonia isn’t an established side effect, but some case reports and anecdotes describe it.
• GLP-1 receptors in reward pathways offer a possible explanation.
• Psychiatric side effects on GLP-1s appear uncommon overall.
• If you notice mood changes, talk to your provider; dose adjustments may help.

• Gizmodo – People Can Lose Their Zest for Life After Starting GLP-1s, Docs Warn
• Biomolecules (PMC) – Retatrutide: A Game Changer in Obesity Pharmacotherapy
• PMC – Psychiatric Adverse Events Associated With Semaglutide, Liraglutide and Tirzepatide
• PMC – GLP-1 Receptor Agonists and Depression: FAERS and VigiBase Analysis
• CTV News – What Experts Say About Claims of a New Weight-Loss Compound Making People Fall Out of Love
• Drugs.com – Retatrutide FDA Approval Status